TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Erythema Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Aesthetic Improvement Scale (Investigator)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global Aesthetic Improvement Scale (Subject)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: performance on emotion recognition test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change on Wechsler Intelligence Scale for Adults (WAIS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Mini Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypercapnic ventilatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Range of motion of the affected shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life of participants
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electrical or Mechanical Dysynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ullanlinna Narcolepsy Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ki-67 Labeling Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Symptom-Free Days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of aortic valve leaflet thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disposal rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinical metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Sleep Hours During Night Float
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Rapid Eye Movement Sleep Hours During Night Float
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Daily Steps during Night Float Week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of Pain and Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Migration of Sentimark Device
Endpoint domain: Adverse events/effects
Primary endpoint: Achievement rate of serum phosphorus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported improvement in urinary incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Upper respiratory tract viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Angina symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Health service use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Frequency of adverse events (AEs) relating to the stoma
Endpoint domain: Adverse events/effects
Primary endpoint: Injection site and systemic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Executive/Inhibitory skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HIV peptides responded to
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total number of CD8+ lymphocytes responding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time-loss due to first-time non-contact lateral ankle sprains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time-loss due to recurrent non-contact lateral ankle sprains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time-loss due to first-time lateral ankle sprains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time-loss due to recurrent lateral ankle sprains
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Experience a Serious Adverse Events (SAEs) 29 Days After the Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience a Serious Adverse Events (SAEs) During a 6 Month Follow up Period From the Receipt of First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Seroconverted One Month After First Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the score on the Beck Depression Inventory-II (BDI-II)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Macroscopic evaluations for Lacrimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macroscopic evaluations for Bulbar Conjunctiva Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Macroscopic evaluations of Palpebral Conjunctiva Irritation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective assessment of discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average morphine equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum NRS Pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Global Facial Aesthetic Appearance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cerebral oxymetry values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically defined tonsil bleed rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hamilton Depression Scale (HAM-D) 17
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of unintended pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: use of blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of bone marrow fat in vertebral bone marrow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertebral fracture severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-factor Xa concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pathological grades of clear cell renal cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Acquisition of a senescent phenotype in leukocytes and endothelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Proceeded to Surgical Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: remission rate (PCDAI for Crohn's disease)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: remission rate (PUCAI ulcerative colitis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Friedreich Ataxia Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Effectiveness as Measured by Visual Field Indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medical Effectiveness as Measured by Glaucoma Hemifield Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VOC Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants showing seroconversion against sero group V. cholerae O1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and AEs leading to discontinuation of study drug
Endpoint domain: Adverse events/effects
Primary endpoint: change in body weight in kilograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in Electrocardiogram (ECG) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Worst Itch Numeric Rating Scale (WI-NRS) Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vaccine-related Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Showing >/=4-fold Rise in Serum Hepatitis E Virus Immunoglobulin G (IgG) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of clinical and wound complications with indwelling chest tube - SEVERE PAIN
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of clinical and wound complications with indwelling chest tube - TUBE DISLODGEMENT
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of clinical and wound complications with indwelling chest tube - PERITUBAL LEAKAGE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with early wound complications after chest tube removal - AIR SUCK-IN
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with early wound complications after chest tube removal - POST-INSERTION WOUND INFECTION
Endpoint domain: Adverse events/effects
Primary endpoint: percentage of 4 BL cells in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Epidermization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of intensity of composite-pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final diagnosis of malignant pancreatic mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Final diagnosis of benign pancreatic mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Navicular Drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average daily mood
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of TAPS
Endpoint domain: Adverse events/effects
Primary endpoint: Perinatal Morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perinatal Survival
Endpoint domain: Mortality/survival
Primary endpoint: Respiratory development - 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete discontinuation of targeted potentially inappropriate medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantitative Global Scaring Grading System (QGSGS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Effects of Atrasentan on heart function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Change in Composite Score from Cognition Assessment Battery
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of hypoglycemia episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients Whose Samples Were Measured for Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-risk recurrence-free survival at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Change in pain intensity in the affected knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of Lequesne's index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between physician's diagnosis and Sleep survey classification
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proteomic markers of differentiated thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Resorption of Study Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of lidocaine ineffectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Afebrile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Effective CRT Pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Macular Drusen Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Drain Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: extent of treatment failures
Endpoint domain: Adverse events/effects
Primary endpoint: complications associated with implantation
Endpoint domain: Adverse events/effects
Primary endpoint: Gastric cross sectional area diameter change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Glycemic metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental Cost Efficiency Rate (ICER)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postprandial Glucose Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Colony-forming units (CFU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference in regional brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in Disease activity score (DAS28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Pain VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution of autoreactive B cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of chronic graft-versus-host disease (GHVD)
Endpoint domain: Adverse events/effects
Primary endpoint: Participant consent rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Human papillomavirus (HPV) self-collection uptake rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response to DTM SCS Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in functional connectivity maps (EEG coherence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction of clinical outcomes based on pre-treatment EEG functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of PRBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: cGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changed functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Left Ventricular End-Diastolic Volume Index (LV-EDVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left Ventricular End-Systolic Volume Index (LV-ESVi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: two-year overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Quality of Care (QoC)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Accuracy of Pulse Oximeter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of inflammatory markers in gingival crevicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety as Reflected on the Number and Severity of Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Early Feasibility as Reflected on the Number of Participants Contracting COVID-19 (10% or Less) in Comparison to the Expected 30% as Per CDC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of suctions per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse device/procedure effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline on BSI-18 Global Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from Baseline in WBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from Baseline in RBC count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: myosin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in postprandial triglyceride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall Improvement of Acne Scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average Improvement in Surface Texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Degree of Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Development of neuropathic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Difference in Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitamin D 25-OHD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of nocturia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of child participation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Calcium loss from bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Patient information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Erythema degree or absence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation in the sum of the items 32 and 33 (duration and severity of dyskinesias)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composition of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: functional capacity for aerobic exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional reserve as measured by the reduction in breathlessness and fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in the spectrum of patient reported symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hemophilia at the end of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Family Caregiver Medication Administration Hassle Scale
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Number of shivering episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of TMC435350
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of TMC435350
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between color status and pH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major functional disability (MFD)-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants who experience graft versus host disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Hearing Performance, PTA4 at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hearing Performance, PTA4 at 36 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colonic wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Color and power Doppler vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mesenteric lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cognitive disorder (Mini-Mental State Examination)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detectable levels of inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Primary Problem chosen by the patient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Difference in Astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Rescue Antiemetics Requirement
Endpoint domain: Adverse events/effects
Primary endpoint: serum inflammatory marker Interleukine-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes